

(19)



(11)

EP 2 992 903 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(51) International Patent Classification (IPC):

A61K 47/60 ^(2017.01) **A61K 45/06** ^(2006.01)
A61P 39/00 ^(2006.01) **C07D 489/04** ^(2006.01)

(48) Corrigendum issued on:

08.06.2022 Bulletin 2022/23

(52) Cooperative Patent Classification (CPC):

A61K 47/60; A61P 25/00; A61P 25/04;
A61P 39/00; C07D 489/04; C07B 2200/13

(45) Date of publication and mention of the grant of the patent:

15.07.2020 Bulletin 2020/29

(21) Application number: **15188944.1**

(22) Date of filing: **29.09.2011**

(54) COMBINATION OF A NALOXOL-PEG CONJUGATE AND AN OPIOID AGONIST

KOMBINATION VON EINEM NALOXOL-PEG-KONJUGATE UND EINEM OPIOIDAGONIST

COMBINAISON D'UN CONJUGUÉ NALOXOL-PEG AVEC UN AGONISTE OPIOÏDE

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

Designated Extension States:

BA ME

- **BOHLIN, Martin Hans**
151 85 Södertälje (SE)
- **SEBHATU, Tesfai**
151 85 Södertälje (SE)
- **YMEN, Bo Ingvar**
151 85 Södertälje (SE)
- **HEALY, Eric Thomas**
San Francisco, CA 94158 (US)
- **JENSEN, David Richard**
San Francisco, CA 94158 (US)
- **JONAITIS, David Thomas**
West Lafayette, IN 47906-1076 (US)
- **PARENT, Stephan**
West Lafayette, IN 47906-1076 (US)
- **LECHUGA-BALLESTEROS, David**
San Jose, CA 95124 (US)

(30) Priority: **30.09.2010 US 388501 P**

(43) Date of publication of application:

09.03.2016 Bulletin 2016/10

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

11829686.2 / 2 621 496

(73) Proprietors:

- **AstraZeneca AB**
151 85 Södertälje (SE)
- **Nektar Therapeutics**
San Francisco, CA 94158 (US)

(74) Representative: **Boult Wade Tennant LLP**
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP (GB)

(72) Inventors:

- **ASLUND, Bengt Leonard**
151 85 Södertälje (SE)
- **AURELL, Carl-Johan**
151 85 Södertälje (SE)

(56) References cited:

WO-A1-2009/137086 WO-A2-2005/058367
WO-A2-2008/057579

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 992 903 B8

- NEUMANN THERESA A ET AL: "Evaluation of single oral doses of NKTR118 (PEG-naloxol) as a peripheral opioid antagonist (POA): A double-blind placebo-controlled study in healthy male subjects", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 9, 118, 1 September 2007 (2007-09-01), page 1210, XP009120642, ISSN: 0091-2700
- ODINEES A ET AL: "NKTR-118, AN ORAL PERIPHERAL OPIOID ANTAGONIST, HAS LOW POTENTIAL FOR DRUG-DRUG INTERACTIONS", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 49, no. 9, 141, September 2009 (2009-09), page 1123, XP009120650, & 38TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-CLINICAL-PHARMACOLOGY; SAN ANTONIO, TX, USA; SEPTEMBER 13 -15, 2009 ISSN: 0091-2700 Retrieved from the Internet:
URL:<http://onlinelibrary.wiley.com/doi/10.1177/00912700090490091001/pdf>>
- NEUMANN T A ET AL: "Clinical investigation of NKTR-118 as a selective oral peripheral opioid antagonist", POSTER PRESENTED AT THE ANNUAL CLINICAL MEETING OF THE AMERICAN ACADEMY OF PAIN MANAGEMENT ; SEPTEMBER 27-30, 2007; LAS VEGAS, NV,, 27 September 2007 (2007-09-27), page POSTER27, XP001586734,
- ELDON M A ET AL: "NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone; demonstration of selective peripheral opioid antagonism after oral administration in preclinical models", POSTER PRESENTED AT THE ANNUAL CLINICAL MEETING OF THE AMERICAN ACADEMY OF PAIN MANAGEMENT ; SEPTEMBER 27-30, 2007; LAS VEGAS, NV,, [Online] 27 September 2007 (2007-09-27), page POSTER28, XP001586735, Retrieved from the Internet: URL:<http://www.nektar.com>>